Post marketing study to evaluate the efficacy and safety of Magics hair powder in subject with male pattern hair loss

A prospective, open-label, interventional, non-comparative, multi-centric active post-marketing surveillance to evaluate the efficacy and safety of Magics hair powder in subjects with male-pattern hair loss - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2024/02/063186

Enrollment

Registered

2024-02-27

Start date

Unknown

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L659- Nonscarring hair loss, unspecified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1.Healthy male subjects in the age range of 18 to 50 years 2.Subjects which are â??not bald ?, and have type I to type III male-pattern hair loss according to Hamilton classification 3.Subjects willing to give written informed consent 4.Subjects agreed not to use any medication, including vitamins and minerals, or any cosmetic products during the course of this study, which are designed to impact hair health

Exclusion criteria

Exclusion criteria: 1.Subjects with a history of allergic or sensitivity reactions to any cosmetic products 2.Subject with known hypersensitivity to any specific ingredients of investigational product 3.Subjects previously undergone hair transplantation procedures 4.Subjects with skin diseases 5.Subjects being treated for hair fall or severe active infection of any type 6.Subject with underlying significant uncontrolled medical illness such as cardiovascular, respiratory, renal, gastrointestinal, hepatic, immunologic, hematological, endocrine, or nervous systems or psychiatric disease 7.HIV positive subjects 8.Subjects with pre-existing scalp disorder such as scalp psoriasis, lichen planus, lichen planopilaris, discoid lupus erythematosus, sebopsoriasis except dandruff 9.Subjects participated in a clinical trial within 30 days prior to screening 10.Any other health or mental condition that in the Investigatorâ??s opinion may adversely affect the ability to complete the study or its measures or that may pose significant risk to the subject

Design outcomes

Primary

Measure	Time frame
â?¢Dermatological assessments such as hair comb test, hair thinning, hair fall test, and hair pull test â?¢Instrumental assessments such as hair growth rate, hair density, anagen hair, telogen hair, the density of vellus hair and terminal hair using trichoscope â?¢Participant self-assessment questionnaire â?¢Participant quality of life questionnaire Timepoint: Day-0,Day15,Day-30,Day-45,Day-60,Day-90	—

Measure

Time frame

â?¢Dermatological assessments such as hair comb test, hair thinning, hair fall test, and hair pull test â?¢Instrumental assessments such as hair growth rate, hair density, anagen hair, telogen hair, the density of vellus hair and terminal hair using trichoscope â?¢Participant self-assessment questionnaire â?¢Participant quality of life questionnaire Timepoint: Day-0,Day15,Day-30,Day-45,Day-60,Day-90

—

Secondary

Measure	Time frame
â?¢ Any adverse event or serious adverse event reported on hair & scalp conditions during course of the studyTimepoint: Day-0,Day15,Day-30,Day-45,Day-60,Day-90	—

Countries

India

Contacts

Public ContactDrAnkit Trivedi

Consultant Ayurvedic physician, Aatman Hospital

drankittrivedicr@gmail.com7990925289

Outcome results